Voyager Therapeutics, INC Form 4 insider transactions

Steven Hyman, a Director at Voyager Therapeutics, Inc. (VYGR), was granted 24,000 stock options with an exercise price of $3.28 per share as part of the company's 2025 Stock Incentive Plan.

Voyager Therapeutics, Inc. Director Michael J. Higgins was granted 24,000 stock options with an exercise price of $3.28 per share, vesting based on continued service.

Voyager Therapeutics, Inc. Director James A. Geraghty was granted 24,000 stock options with an exercise price of $3.28 as part of the company's 2025 Stock Incentive Plan.

Voyager Therapeutics, Inc. Director Grace Colon was granted 24,000 stock options with an exercise price of $3.28, vesting based on continued service.

Toby Ferguson, Chief Medical Officer of Voyager Therapeutics, sold 10,086 shares of common stock to cover tax obligations related to vesting restricted stock units.

Voyager Therapeutics CEO Alfred Sandrock sold 10,885 shares of common stock on April 2, 2025, to cover tax obligations related to vesting restricted stock units.

Chief Scientific Officer Todd Alfred Carter reports the sale of shares to cover tax obligations and the acquisition of restricted stock units and stock options in Voyager Therapeutics.

CEO Alfred Sandrock of Voyager Therapeutics reports the sale of shares to cover tax obligations and the acquisition of restricted stock units and stock options.

Robin Swartz, COO & CBO of Voyager Therapeutics, reports the sale of shares to cover tax obligations and the acquisition of restricted stock units and stock options.

Jacquelyn Fahey Sandell, Chief Legal Officer of Voyager Therapeutics, reports the acquisition of stock and option awards.

Chief Medical Officer of Voyager Therapeutics, Toby Ferguson, reports acquisition of restricted stock units and stock options, along with the disposal of common stock.

Chief Financial Officer of Voyager Therapeutics, Nathan D. Jorgensen, reports the acquisition of stock and option awards.

Todd Alfred Carter, Chief Scientific Officer of Voyager Therapeutics, sold 5,413 shares of common stock to cover tax obligations related to vesting restricted stock units.

Robin Swartz, COO & CBO of Voyager Therapeutics, sold 6,950 shares of common stock to cover tax obligations related to vesting restricted stock units.

Voyager Therapeutics CEO Alfred Sandrock sold 16,644 shares of common stock on February 11, 2025, to cover tax withholding obligations related to vesting restricted stock units.

Jacquelyn Fahey Sandell, Chief Legal Officer of Voyager Therapeutics, sold shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Robin Swartz, COO & CBO of Voyager Therapeutics, sold 3,087 shares of common stock at an average price of $5.09 on January 14, 2025.

Todd Alfred Carter, Chief Scientific Officer of Voyager Therapeutics, sold 1,191 shares of common stock at an average price of $5.13 on January 14, 2025.

Robin Swartz, COO & CBO of Voyager Therapeutics, sold 6,500 shares of common stock at an average price of $5.65 on December 23, 2024.

Jacquelyn Fahey Sandell, Chief Legal Officer of Voyager Therapeutics, sold 5,999 shares of common stock to cover tax obligations related to vesting restricted stock units.

Nathan D. Jorgensen, CFO of Voyager Therapeutics, acquired 80,000 shares of common stock through a restricted stock unit (RSU) award as an inducement for employment.

Nathan Jorgensen, CFO of Voyager Therapeutics, was granted stock options as an inducement to join the company.

Director Nancy Vitale acquired 24,000 stock options in Voyager Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing.

Director George A. Scangos acquired 24,000 stock options in Voyager Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing with the SEC.

Director Glenn Pierce acquired 24,000 stock options in Voyager Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing with the SEC.

Director Jude Onyia acquired 24,000 stock options in Voyager Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing.

Director Catherine J. Mackey acquired 24,000 stock options in Voyager Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing.

Director Steven Hyman acquired 24,000 stock options in Voyager Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing.

Director Michael J. Higgins acquired 24,000 stock options in Voyager Therapeutics, Inc. on June 5, 2024.

Director James A. Geraghty receives stock options from Voyager Therapeutics under the 2015 Stock Option and Incentive Plan.